drugset / Trial / NCT01703065
Cabozantinib in Men With Castration-Resistant Prostate Cancer
Phase 2
Terminated
9 enrolled
University of Washington
National Cancer Institute (NCI) · collabProstate Cancer Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-06-18
- Primary completion
- 2015-02-02
- Completion
- 2015-09-18
Outcome
Outcome not reported
Stopped (Enrollment): “Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |